# @dexcom on Instagram

- **Type:** Video
- **Original URL:** https://www.instagram.com/p/DCEyg3mNQ4a
- **Gondola URL:** https://gondola.cc/posts/24676774-dexcom-instagram
- **Thumbnail:** https://img.gondola.cc/tr:w-,h-,fo-auto/postThumbnails/cd1405a3dc.jpg
- **Posted:** 2024-11-07T15:16:17.000+00:00
- **Account Owner:** Dexcom (@dexcom) — https://gondola.cc/dexcom

## Caption

Say hello to the Dexcom G7 + omnipod® 5 duo – the 1st and only waterproof*† AID system for people with type 1 and type 2 diabetes. 
.
The most accurate CGM powering AID systems are now integrated with the Omnipod 5 Automated Insulin Delivery System, providing you with seamless connectivity, helping to keep you in range1-3, without multiple daily injections or fingersticks ‡ ! 
.
Visit our link in bio to find out if the Omnipod 5 System is right for you. 
.
#MadeForConnections #DexcomG7 #Omnipod5 #DexcomAID #DiabetesTech 
.
*The Dexcom G7 Sensor is waterproof and may be submerged under eight feet of water for up to 24 hours without failure when properly installed. 
† The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Personal Diabetes Manager and Controller are not waterproof. 
 ‡ Fingersticks required for diabetes treatment decision if symptoms or expectations do not match readings. Pod shown without necessary adhesive. 
1 Study in 240 people with T1D aged 6 - 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 in adults/adolescents and children = 64.7% vs. 73.9%; 52.5% vs. 68.0%. Brown S. et al. Diabetes Care (2021). 
2 Study in 80 people with T1D aged 2 - 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 = 57.2% vs. 68.1%. Sherr JL, et al. Diabetes Care (2022). 
3 Pasquel FJ, et al. Presented at: ADA; June 21-24, 2024; Orlando, FL. Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. Mean time in range (70-180 mg/dL): ST vs. 13-week Omnipod 5: 45% vs. 66%, P<0.001.

## Stats

- **Views:** 0
- **Likes:** 481
- **Shares:** 0
- **Comments:** 21

## Tags

omnipod5, diabetestech, madeforconnections, dexcomg7, dexcomaid

---
Copyright (c) Gondola